Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Drug Alcohol Depend ; 253: 111029, 2023 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-38006669

RESUMEN

BACKGROUND: Mindfulness-based interventions are increasingly used for the treatment of substance use disorders, including methamphetamine use disorder (MUD). Literature indicates that trait mindfulness may play a key role in the effectiveness of these treatments on therapeutic outcome, yet no prior studies have tested for differences in trait mindfulness between individuals with MUD and healthy control participants. Such differences are important for treatment implementation. OBJECTIVES: The goals of this study were to evaluate trait mindfulness and to determine its clinical correlates in individuals with MUD. METHODS: A group of participants with MUD at varying lengths of abstinence from methamphetamine (< 1h to 90 days; mean 5.4 ± 12.5 days; N=95, 53 female, 42 male) and a healthy control group (N=65, 30 female, 35 male) completed the Mindfulness Attention Awareness Scale (MAAS). Group differences and relationships between trait mindfulness and several measures of drug use and psychiatric symptoms were evaluated. RESULTS: In participants with MUD, trait mindfulness was 10% lower than in healthy controls (p < 0.001), but it was not significantly correlated with measures of drug use or craving. Across both groups, trait mindfulness was negatively correlated with state anxiety, depression, emotional dysregulation, impulsivity, and a history of childhood trauma, while it was positively correlated with self-compassion (ps < 0.001). CONCLUSION: The deficit in trait mindfulness in MUD presents a capacity that can be targeted for improved treatment outcome with mindfulness-based therapies. Trait mindfulness is inversely related to mood dysregulation.


Asunto(s)
Metanfetamina , Atención Plena , Trastornos Relacionados con Sustancias , Humanos , Masculino , Femenino , Metanfetamina/efectos adversos , Trastornos Relacionados con Sustancias/psicología , Resultado del Tratamiento , Afecto
2.
Am J Drug Alcohol Abuse ; 45(6): 563-579, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31365275

RESUMEN

Background: Cannabis is the most widely used illicit substance worldwide, and legalization for recreational and medical purposes has substantially increased its availability and use in the United States.Objectives: Decades of research have suggested that recreational cannabis use confers risk for cognitive impairment across various domains, and structural and functional differences in the brain have been linked to early and heavy cannabis use.Methods: With substantial evidence for the role of the endocannabinoid system in neural development and understanding that brain development continues into early adulthood, the rising use of cannabis in adolescents and young adults raises major concerns. Yet some formulations of cannabinoid compounds are FDA-approved for medical uses, including applications in children.Results: Potential effects on the trajectory of brain morphology and cognition, therefore, should be considered. The goal of this review is to update and consolidate relevant findings in order to inform attitudes and public policy regarding the recreational and medical use of cannabis and cannabinoid compounds.Conclusions: The findings point to considerations for age limits and guidelines for use.


Asunto(s)
Encéfalo/efectos de los fármacos , Cannabidiol/farmacología , Cognición/efectos de los fármacos , Dronabinol/farmacología , Marihuana Medicinal/uso terapéutico , Factores de Edad , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Trastorno del Espectro Autista/tratamiento farmacológico , Encéfalo/patología , Cannabidiol/uso terapéutico , Endocannabinoides/metabolismo , Epilepsias Mioclónicas/tratamiento farmacológico , Humanos , Lactante , Síndrome de Lennox-Gastaut/tratamiento farmacológico , Tamaño de los Órganos , Espasmos Infantiles/tratamiento farmacológico
3.
Int J Neuropsychopharmacol ; 22(4): 286-291, 2019 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-30753467

RESUMEN

BACKGROUND: Selective serotonin reuptake inhibitors are often used in alcohol use disorders. Clinical trials with selective serotonin reuptake inhibitors for alcohol use disorders, however, have yielded mixed results. The goal of this project was to assess whether a single i.v. dose of a selective serotonin reuptake inhibitor reduces craving for alcohol and/or simultaneously increases striatal dopamine concentration in individuals with alcohol dependence. METHODS: Alcohol-dependent (DSM-IV-TR criteria) volunteers and matched controls (n = 10/group) underwent a double-blind, placebo-controlled, within-subjects study. Participants received i.v. citalopram (40 mg) or saline (counter-balanced) followed by a cue-induced craving assessment and [18F]-fallypride positron emission tomography scanning. RESULTS: In the alcohol-dependent individuals, the citalopram (compared with saline) resulted in decreased cue-induced craving for alcohol. For the whole study group, cue-induced alcohol craving was inversely correlated with thalamic (but not striatal) dopamine D2/3 receptor availability. CONCLUSIONS: Acute serotonin reuptake inhibition reduces cue-induced alcohol craving. Furthermore, thalamic dopamine abnormalities and the striatal hyperdopaminergic hypothesis of alcohol use disorder are supported.


Asunto(s)
Alcoholismo/tratamiento farmacológico , Citalopram/farmacocinética , Cuerpo Estriado/efectos de los fármacos , Ansia/efectos de los fármacos , Receptores de Dopamina D2/efectos de los fármacos , Receptores de Dopamina D3/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/farmacocinética , Tálamo/efectos de los fármacos , Administración Intravenosa , Adulto , Benzamidas , Citalopram/administración & dosificación , Señales (Psicología) , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Pirrolidinas , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación
4.
Psychopharmacology (Berl) ; 231(13): 2717-24, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24535652

RESUMEN

RATIONALE: Findings from animal studies and human PET imaging indicate that nicotine and cigarette smoking affect glutamate (Glu) and related neurochemical markers in the brain and imply that smoking reduces extracellular Glu. As Glu release is mediated by nicotinic acetylcholine receptors (nAChRs), which are present at high concentrations in the thalamus, we examined the effects of smoking on thalamic Glu. OBJECTIVE: To determine the effects of tobacco smoking on thalamic glutamate levels. METHODS: Thalamic Glu levels were measured in vivo in 18 smokers and 16 nonsmokers using proton magnetic resonance spectroscopic imaging ((1)H MRSI) at 1.5 T. RESULTS: Mean Glu levels did not differ significantly between the subject groups. However, within smokers, Glu levels were negatively correlated with self-reports of both cigarettes/day over the last 30 days (r = -0.64, p = 0.006) and pack-years of smoking (r = -0.66, p = 0.005). CONCLUSIONS: Consistent with expectations based on preclinical studies, within smokers, cigarettes/day and pack-years are associated with reduced Glu in thalamus, a brain region rich in nAchRs. These results encourage work on candidate glutamatergic therapies for smoking cessation and suggest a noninvasive metric for their action in the brain.


Asunto(s)
Ácido Glutámico/metabolismo , Receptores Nicotínicos/metabolismo , Fumar/metabolismo , Tálamo/metabolismo , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Espectroscopía de Protones por Resonancia Magnética/métodos , Factores de Tiempo
5.
J Adolesc Health ; 53(1): 139-41, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23601502

RESUMEN

PURPOSE: Because impulsivity during adolescence predicts health-risk behaviors and associated harm, interventions that attenuate impulsivity may offer protection. We evaluated effects of the Youth Empowerment Seminar (YES!), a biopsychosocial workshop for adolescents that teaches skills of stress management, emotion regulation, conflict resolution, and attentional focus, on impulsive behavior. METHODS: High school students (14-18 years of age) in the United States participated in YES! during their physical education classes. Students in a control group attended their usual curriculum and were tested in parallel. We used items from the Barratt Impulsiveness Scale (framed to reflect recent behavior) to assess students' behavior before and after they underwent the program. RESULTS: Compared with the control group, YES! participants reported less impulsive behavior after the program. CONCLUSIONS: The results suggest that YES! can promote mental health in adolescents, potentially protecting them from harmful coping behaviors.


Asunto(s)
Educación en Salud/métodos , Conducta Impulsiva/prevención & control , Adolescente , Femenino , Humanos , Los Angeles , Masculino , Terapias Mente-Cuerpo/métodos , Pruebas Psicológicas , Psicología del Adolescente , Asunción de Riesgos , Adulto Joven
6.
Synapse ; 63(9): 817-21, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19504620
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA